

Date: April 9, 1997.

Time: 3:00 p.m.

Place: NIH, Rockledge 2, Room 4138, Telephone Conference.

Contact Person: Dr. Anthony Chung, Scientific Review Administrator, 6701 Rockledge Drive, Room 4138, Bethesda, Maryland 20892, (301) 435-1213.

Name of SEP: Clinical Sciences.

Date: April 14, 1997.

Time: 10:45 a.m.

Place: NIH, Rockledge 2, Room 4140, Telephone Conference.

Contact Person: Dr. Larry Pinkus, Scientific Review Administrator, 6701 Rockledge Drive, Room 4140, Bethesda, Maryland 20892, (301) 435-1214.

Name of SEP: Clinical Sciences.

Date: April 15, 1997.

Time: 1:00 [p.m.]

Place: NIH, Rockledge 2, Room 4112, Telephone Conference.

Contact Person: Dr. Gopal Sharma, Scientific Review Administrator, 6701 Rockledge Drive, Room 4112, Bethesda, Maryland 20892, (301) 435-1783.

Name of SEP: Clinical Sciences.

Date: April 17, 1997.

Time: 1:00 p.m.

Place: NIH, Rockledge 2, Room 4112, Telephone Conference.

Contact Person: Dr. Gopal Sharma, Scientific Review Administrator, 6701 Rockledge Drive, Room 4112, Bethesda, Maryland 20892, (301) 435-1783.

Name of SEP: Clinical Sciences.

Date: April 21, 1997.

Time: 2:00 p.m.

Place: NIH, Rockledge 2, Room 4100, Telephone Conference.

Contact Person: Dr. Jeanne N. Ketley, Scientific Review Administrator, 6701 Rockledge Drive, Room 4100, Bethesda, Maryland 20892, (301) 435-1789.

Name of SEP: Biological and Physiological Sciences.

Date: April 22, 1997.

Time: 1:30 p.m.

Place: NIH, Rockledge 2, Room 5196, Telephone Conference.

Contact Person: Ms. Carol Campbell, Scientific Review Administrator, 6701 Rockledge Drive, Room 5196, Bethesda, Maryland 20892, (301) 435-1257.

Name of SEP: Clinical Sciences.

Date: April 23, 1997.

Time: 2:00 p.m.

Place: NIH, Rockledge 2, Room 4100, Telephone Conference.

Contact Person: Dr. Jeanne N. Ketley, Scientific Review Administrator, 6701 Rockledge Drive, Room 4100, Bethesda, Maryland 20892, (301) 435-1789.

Purpose/Agenda: To Review Small Business Innovation Research.

Name of SEP: Microbiological and Immunological Sciences.

Date: April 4, 1997.

Time: 8:00 a.m.

Place: Doubletree Hotel, Rockville, MD.

Contact Person: Dr. Gilbert Meier, Scientific Review Administrator, 6701 Rockledge Drive, Room 4200, Bethesda, Maryland 20892, (301) 435-1219.

The meetings will be closed in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5, U.S.C. Applications and/or proposals and the discussions could reveal confidential trade secrets or commercial property such as patentable material and personal information concerning individuals associated with the applications and/or proposals, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

(Catalog of Federal Domestic Assistance Program Nos. 93.306, 93.333, 93.337, 93.393-93.396, 93.837-93.844, 93.846-93.878, 93.892, 93.893, National Institutes of Health, HHS)

Dated: March 14, 1997.

LaVerne Y. Stringfield,

Committee Management Officer, NIH.

[FR Doc. 97-6941 Filed 3-18-97; 8:45 am]

BILLING CODE 4140-01-M

Prospective Grant of Exclusive License: Method of Treating Established Colitis Using Antibodies Against IL-12

AGENCY: National Institutes of Health, Public Health Service, DHHS.

ACTION: Notice.

SUMMARY: This notice, in accordance with 35 U.S.C. 209(c)(1) and 37 CFR 404.7(a)(1)(I), announces that the National Institutes of Health is contemplating the grant of a co-exclusive world-wide license to Genetics Institute, Inc., a Delaware corporation headquartered in Cambridge, Massachusetts, and Protein Design Lab, Inc., a Delaware corporation headquartered in Mountain View, California, to practice the inventions embodied in U.S. Patent Application 08/547,979 and corresponding foreign patent applications entitled "Method of Treating Established Colitis Using Antibodies Against IL-12" in the field of treatment of inflammatory bowel disease. These inventions are owned by the Government of the United States of America as represented by the Department of Health and Human Services.

The prospective exclusive license will be royalty-bearing and will comply with the terms and conditions of 35 U.S.C. 209 and 37 CFR 404.7. The prospective exclusive license may be granted unless within sixty (60) days from the date of this published notice, NIH receives written evidence and argument that establishes that the grant of the license would not be consistent with the requirements of 35 U.S.C. 209 and 37 CFR 404.7.

SUPPLEMENTARY INFORMATION: The patent application discloses a method of treating the established criteria colitis of

an inflammatory bowel disease by administering the antibodies against IL-12. A method for evaluating the effectiveness of the IL-12 antibodies in reducing the inflammatory response is also presented.

ADDRESSES: Requests for copies of the patent applications, inquiries, comments and other materials relating to the contemplated licenses should be directed to: Jaconda Wagner, J.D., Technology Licensing Specialist, Office of Technology Transfer, National Institutes of Health, 6011 Executive Boulevard, Suite 325, Rockville, Maryland 20852-3804; Telephone: (301) 496-7735, ext. 284; Facsimile: (301) 402-0220. A signed Confidentiality Agreement will be required to receive copies of the patent applications. Applications for a license in the field of use filed in response to this notice will be treated as objections to the grant of the contemplated licenses. Only written comments and/or applications for a license which are received by NIH on or before May 19, 1997, will be considered. Comments and objections submitted to this notice will not be made available for public inspection and, to the extent permitted by law, will not be released under the Freedom of Information Act, 5 U.S.C. 552.

Dated: March 11, 1997.

Barbara M. McGarey,

Deputy Director, Office of Technology Transfer.

[FR Doc. 97-6856 Filed 3-18-97; 8:45 am]

BILLING CODE 4140-01-M

DEPARTMENT OF THE INTERIOR

Fish and Wildlife Service

Notice of Availability of the Draft Environmental Assessment and Land Protection Plan for the Proposed Establishment of Black Bayou Lake National Wildlife Refuge, Ouachita Parish, LA

AGENCY: Fish and Wildlife Service, Interior.

ACTION: Notice of availability of the Draft Environmental Assessment and Land Protection Plan for the Proposed Plan for the Proposed Establishment of Black Bayou Lake National Wildlife Refuge.

SUMMARY: This notice advises the public that the U.S. Fish and Wildlife, Southeast Region, proposes to establish a new national wildlife refuge on Black Bayou lake near the city of Monroe in Ouachita Parish, Louisiana. The purpose of the proposed refuge is to